What Nuvation Bio Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 1 |
| Sells | 1 | 16 |
| Total trades | 2 | 38 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
Common stock only — 38 reported trades in the last 12 months are in a security these totals do not cover.
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Aug 19 | Open-market sale · S | −100,000 | $7.09 | −$709K | 0 |
| Hattersley Gary | CHIEF SCIENTIFIC OFFICER | Aug 19 | Exercise / conversion · M | +100,000 | $1.87 | +$187K | 100,000 |
| Sauvage Philippe | Chief Financial Officer | Jul 15 | Exercise / conversion · M | +1 | $1.97 | +$1.97 | 54,131 |
| Sauvage Philippe | Chief Financial Officer | Jul 15 | Exercise / conversion · M | +39,999 | $2.17 | +$86.8K | 54,130 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Jun 23 | Open-market sale · S | −63,000 | $6.02 | −$379K | 53,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Jun 23 | Exercise / conversion · M | +63,000 | $2.93 | +$185K | 116,000 |
| Markel Stacy | CHIEF PEOPLE OFFICER | Jun 23 | Open-market sale · S | −125,000 | $6.03 | −$753K | 32,591 |
| Markel Stacy | CHIEF PEOPLE OFFICER | Jun 23 | Exercise / conversion · M | +34,620 | $1.74 | +$60.2K | 157,591 |
| Markel Stacy | CHIEF PEOPLE OFFICER | Jun 23 | Exercise / conversion · M | +90,380 | $1.87 | +$169K | 122,971 |
| Sauvage Philippe | Chief Financial Officer | Jun 23 | Open-market sale · S | −47,668 | $6.01 | −$286K | 12,673 |
| Sauvage Philippe | Chief Financial Officer | Jun 23 | Exercise / conversion · M | +47,668 | $2.17 | +$103K | 60,341 |
| Mashal Robert | Director | Jun 09 | Open-market buy · P | +25,000 | $4.73 | +$118K | 225,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 17 | Open-market sale · S | −36,750 | $5.01 | −$184K | 53,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 17 | Exercise / conversion · M | +36,750 | $2.93 | +$108K | 89,750 |
| Liu Dongfang | CHIEF MEDICAL OFFICER | Apr 17 | Open-market sale · S | −50,000 | $5.02 | −$251K | 18,000 |
| Liu Dongfang | CHIEF MEDICAL OFFICER | Apr 17 | Exercise / conversion · M | +50,000 | $1.94 | +$97K | 68,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 06 | Open-market sale · S | −200,000 | $4.52 | −$904K | 53,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 06 | Exercise / conversion · M | +100,000 | $1.94 | +$194K | 253,000 |
| Wentworth Kerry | CHIEF REGULATORY OFFICER | Apr 06 | Exercise / conversion · M | +100,000 | $1.87 | +$187K | 153,000 |
| Makunje Moses | SEE REMARKS | Feb 27 | Grant / award · A | +50,761 | — | — | 68,137 |
Loading...
